Literature DB >> 8723448

Concentrations of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis.

M Karlsson1, S Hammers, I Nilsson-Ehle, A S Malmborg, B Wretlind.   

Abstract

Concentrations of doxycycline and penicillin G in serum and cerebrospinal fluid (CSF) were analyzed in 46 patients during treatment for neuroborreliosis. Twenty patients were treated intravenously with penicillin G at 3 g every 6 h (q6h), and 26 patients were treated orally with doxycycline at 200 mg q24h. All samples were collected on day 13 of treatment. The median concentrations of penicillin G in serum were 0.5, 37, and 5.6 micrograms/ml before and 1 and 3 h after drug administration, and that in CSF was 0.5 (range, 0.3 to 1.6) microgram/ml after 2 to 3 h. The median concentrations of doxycycline in serum were 2.1, 6.1, and 4.7 micrograms/ml before and 2 and 6 h after drug administration, and that in CSF was 0.6 (range, 0.4 to 2.5) microgram/ml after 4 h. All patients had concentrations of penicillin G or doxycycline in CSF above the lowest reported MICs of penicillin G (0.003 microgram/ml) and doxycycline (0.12 microgram/ml) for Borrelia burgdorferi. However, no patients had a drug concentration in CSF above the highest reported MIC of penicillin G (8 micrograms/ml), and only one had a drug concentration in CSF above the highest reported MIC of doxycycline (2 micrograms/ml), despite good clinical response to treatment. No treatment failure or relapse was observed during a 1-year follow-up, although one patient treated with penicillin G and one treated with doxycycline were retreated because of residual pain. The chosen dosages of penicillin G and doxycycline seem to give sufficient concentrations in serum and CSF for the treatment of neuroborreliosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8723448      PMCID: PMC163273          DOI: 10.1128/AAC.40.5.1104

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

1.  Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents.

Authors:  R C Johnson; C B Kodner; P J Jurkovich; J J Collins
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 2.  Antibiotic treatment in Lyme borreliosis.

Authors:  A Philipson
Journal:  Scand J Infect Dis Suppl       Date:  1991

3.  Detection of Borrelia burgdorferi DNA in urine samples and cerebrospinal fluid samples from patients with early and late Lyme neuroborreliosis by polymerase chain reaction.

Authors:  A M Lebech; K Hansen
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

4.  Clinical and microbiologic findings in six patients with erythema migrans of Lyme disease.

Authors:  B W Berger; R C Johnson
Journal:  J Am Acad Dermatol       Date:  1989-12       Impact factor: 11.527

5.  Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neuroborreliosis.

Authors:  M Karlsson; S Hammers-Berggren; L Lindquist; G Stiernstedt; B Svenungsson
Journal:  Neurology       Date:  1994-07       Impact factor: 9.910

6.  Roxithromycin in Lyme borreliosis: discrepant results of an in vitro and in vivo animal susceptibility study and a clinical trial in patients with erythema migrans.

Authors:  K Hansen; A Hovmark; A M Lebech; K Lebech; I Olsson; L Halkier-Sørensen; E Olsson; E Asbrink
Journal:  Acta Derm Venereol       Date:  1992-08       Impact factor: 4.437

7.  Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis.

Authors:  H W Pfister; V Preac-Mursic; B Wilske; E Schielke; F Sörgel; K M Einhäupl
Journal:  J Infect Dis       Date:  1991-02       Impact factor: 5.226

8.  Penicillin G sodium and ceftriaxone in the treatment of neuroborreliosis in children--a prospective study.

Authors:  R R Müllegger; M M Millner; G Stanek; K D Spork
Journal:  Infection       Date:  1991 Jul-Aug       Impact factor: 3.553

9.  Cultivation and characterization of spirochetes from cerebrospinal fluid of patients with Lyme borreliosis.

Authors:  M Karlsson; K Hovind-Hougen; B Svenungsson; G Stiernstedt
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

10.  Cefotaxime vs penicillin G for acute neurologic manifestations in Lyme borreliosis. A prospective randomized study.

Authors:  H W Pfister; V Preac-Mursic; B Wilske; K M Einhäupl
Journal:  Arch Neurol       Date:  1989-11
View more
  20 in total

1.  Antagonism of azole activity against Candida albicans following induction of multidrug resistance genes by selected antimicrobial agents.

Authors:  K W Henry; M C Cruz; S K Katiyar; T D Edlind
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 2.  Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.

Authors:  Roland Nau; Fritz Sörgel; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

3.  Diagnosis and treatment of the neuromuscular manifestations of lyme disease.

Authors:  John J Halperin
Journal:  Curr Treat Options Neurol       Date:  2007-03       Impact factor: 3.598

Review 4.  Antimicrobial susceptibility of Borrelia burgdorferi sensu lato: what we know, what we don't know, and what we need to know.

Authors:  Klaus-Peter Hunfeld; Volker Brade
Journal:  Wien Klin Wochenschr       Date:  2006-11       Impact factor: 1.704

5.  Combining Ceftriaxone with Doxycycline and Daptomycin Reduces Mortality, Neuroinflammation, Brain Damage, and Hearing Loss in Infant Rat Pneumococcal Meningitis.

Authors:  Lukas Muri; Michael Perny; Jonas Zemp; Denis Grandgirard; Stephen L Leib
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

Review 6.  Challenges of repurposing tetracyclines for the treatment of Alzheimer's and Parkinson's disease.

Authors:  Iva Markulin; Marija Matasin; Viktorija Erdeljic Turk; Melita Salković-Petrisic
Journal:  J Neural Transm (Vienna)       Date:  2022-01-04       Impact factor: 3.850

7.  Severe human monocytic ehrlichiosis presenting with altered mental status and seizures.

Authors:  Christian Geier; Jessica Davis; Marc Siegel
Journal:  BMJ Case Rep       Date:  2016-10-06

Review 8.  Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.

Authors:  Nikolas J Onufrak; Alan Forrest; Daniel Gonzalez
Journal:  Clin Ther       Date:  2016-07-20       Impact factor: 3.393

Review 9.  Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.

Authors:  Antonello Di Paolo; Giovanni Gori; Carlo Tascini; Romano Danesi; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2013-07       Impact factor: 6.447

10.  Doxycycline-mediated effects on persistent symptoms and systemic cytokine responses post-neuroborreliosis: a randomized, prospective, cross-over study.

Authors:  Johanna Sjöwall; Anna Ledel; Jan Ernerudh; Christina Ekerfelt; Pia Forsberg
Journal:  BMC Infect Dis       Date:  2012-08-10       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.